The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a new coronavirus disease (COVID-19), which is highly contagious and its pathogenesis has not been fully elucidated. In COVID-19, the inflammation and blood coagulation systems are excessively activated. SARS-CoV- 2 damages endothelial cells and pneumocytes, which leads to disruption of hemostasis in SARS. Thromboembolism is the main cause of mortality in patients with COVID-19. Clots, including pulmonary embolism (PE) and deep vein thrombosis (DVT), ranging from minor to fatal complications of the SARS-CoV-2 infection are known. Individuals with pre-existing diseases are more susceptible to the development of blood clots and poor outcomes. High levels of circulating cytokines and D-dimer (DD) are influential biomarkers of poor outcomes in COVID-19. The latter occurs as a result of hyperfibrinolysis and hypercoagulation. Plasmin is a key player in fibrinolysis and is involved in the cleavage of many viral envelope proteins, including SARS-CoV. Due to this function penetration of viruses into the host cell occurs. In addition, plasmin is involved in the pathophysiology of acute respiratory distress syndrome (ARDS) in SARS and promotes the secretion of cytokines, such as IL-6 and TNF, from activated macrophages. The focus of existing treatment to alleviate fibrinolysis in patients with COVID-19 is the use of systemic fibrinolytic therapy given thrombotic pathology in severe forms of COVID-19 which may lead to death. However, fibrinolytic therapy may be harmful in the advanced stages of COVID-19, when the status of disseminated intravascular coagulation (DIC) changes from suppressed fibrinolysis to its enhancement during the progression of the disease. This narrative review aims to elucidate the pathogenesis of COVID-19, which will further help in precise diagnosis and treatment.

An increase in the hypogalactia frequency diagnosis in breastfeeding mothers is one of the world-spread medical and social problems and is especially high in women with risk factors of lactation disorders. Early estimation of risk factors creates opportunities for physicians to diagnose the lactation problem that mothers face and solve it.

Sports activity is accompanied by intense, long-term, volumetric loads of a specific direction in con-ditions of increased psychological stress, the goal of which is to achieve the maximum possible re-sults for the athlete. Excessive physical load, competi-tive activities, impaired reactivity and resistance of the body reduce the adaptive capabilities of the athletes’ body and often lead to health disorders. Therefore, one of the first tasks in preventing the development of pre-pathological and pathologi-cal conditions in athletes is the timely diagnosis of weak areas and early symptoms of maladaptation.

Measuring anxiety as a personalquality is important as this quality largely determines human behavior.  Analysis of the results showed that the performance of personal anxiety in the subject group ranged from 14 to 29 points. The level of anxiety of 5 people surveyed average with a tendency to low (within 7-15 points), 6 surveyed ranged from 15-25, which corresponds to the average level with tendency to low. 

Glucagon-like peptide-1 receptor agonists (GLP-1-RA) are recommended for the management of type 2 diabetes as well as for obesity treatment. They have multiple effects, including stimulation of insulin secretion, inhibition of glucagon release, gastric emptying delay, and food intake suppression. Type I diabetes melitius (DMT1) requires life-long insulin therapy. However, obesity is caused by overeating; thus, additional insulin injections pose a risk for cardiovascular events, osteoarthritis, and obstructive sleep apnea. In this case report, we inform about a patient with DT1 and binge-eating behavior who used liraglutide 3.0 mg for 3 months for obesity management with significant improvement in HbA1c level (7.5% vs. 6.9%), weight (82.6 vs. 75.2 kg), BMI (32.3 vs. 29.4 kg/m2), waist circumference (94 vs. 88 cm), and leptin level (24.5 vs. 10.3 ng/ml). Further studies of GLP-1-RA in DT1 management can help to reduce the risks of obesity-related conditions and decrease the daily insulin dose requirement.